Here are 18 key notes on orthopedic and spine device companies over the past week.
Mazor signed a commercial and investment agreement with Medtronic.
Medtronic launched Spine Essentials in the United States at the Ambulatory Surgical Center Association annual meeting in Dallas.
Medtronic Spine President Douglas King wrote U.S. senators a letter stating the misplacement of data on its Infuse product was not intentional.
Life Spine completed its initial cases with its PROLIFT Expandable Interbody System.
Xtant Medical's Certex Spinal Fixation System received FDA clearance for the posterior cervical screw indication.
The first spine surgery using MEDTECH's ROSA Spine surgical assistance robot in Spain is now complete.
Histogenics acquired the sole development and commercialization rights to NeoCart for the Japanese market from its development partner Purpose.
The FDA cleared Orthofix's FORZA Peek Titanium Composite Spacer System.
Misonix will soon showcase its new BoneScalpel MIS.
First Ray received FDA 510(k) clearance for its CortiClamp System for small bone fixation.
Bone Solutions received $1.7 million in a recent private placement memorandum.
The U.S. Patent and Trademark Office issued InVivo Therapeutics a Notice of Allowance for the U.S. Patent Application, "Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries."
MiMedx Group filed a lawsuit under the Lanham Act against Osiris Therapeutics for permanent injunctive relief and damages.
The Pittsburgh Venture Capital Association named Blue Belt Technologies Co-Founder Craig Markovitz winner of its 2016 Outstanding Entrepreneur Award.
Novastep entered into an agreement with Vivex Biomedical.
Predictive Technology Group's Predictive Biotech beta launched its molecular diagnostic test for spinal deformities.
Nintendo included health and medical devices in its updated Articles of Incorporations.
Richard Field, MD, professor of orthopedic surgery at St. George's University of London, reported clinical results for Medacta's AMIStem hip implant, which included the finding that the five-year survival rate for the implant was 97.75 percent.